Digital symptom monitoring for adult cancer survivors

Digital Monitoring in Cancer Survivors: a Feasibility Pilot Combining a Smartwatch and Patient-reported Outcome Measures

This project will try using a smartwatch plus regular online ESAS questionnaires to see if digital monitoring is practical and acceptable for adult cancer survivors.

Quick facts

• Study type: Observational
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Betsi Cadwaladr University Health Board (Government)
• Locations: 1 site (Bangor, Gwynedd)
• Trial ID: NCT06669832 on ClinicalTrials.gov

What this trial studies

This observational feasibility project asks adult outpatients with controlled solid tumors to wear a smartwatch continuously while completing the Edmonton Symptom Assessment System (ESAS) via Microsoft Forms on a routine schedule. The study collects passive wearable data and patient-reported outcomes to measure completion rates, data quality, and user satisfaction. Investigators will analyze predictors of attrition and dissatisfaction to inform future digital follow-up programs. No investigational therapies are given and participants must have basic internet and smartphone/SIM capability.

Who should consider this trial

Good fit: Adults (18+) with any solid malignancy who have completed planned treatment, have clinically controlled disease, and have WHO performance status 0–2 while being able to use a smartphone/internet and a SIM card.

Not a fit: Patients without a SIM card or reliable internet access, those unwilling or unable to use mobile data or follow instructions independently, or those with uncontrolled severe illness are unlikely to benefit from this digital monitoring approach.

Why it matters

Potential benefit: If successful, this approach could enable earlier detection of worsening symptoms and improve survivors' quality of life without increasing clinic visits.

How similar studies have performed: Prior studies of electronic patient-reported outcomes and wearable monitoring in cancer populations have shown feasibility and improved symptom detection, though combining continuous smartwatch data with routine ESAS reporting is relatively novel.

Eligibility criteria

Inclusion Criteria:

* • Diagnosis of any solid malignancy, at any stage

  * Completion of treatment (including surgery, radiotherapy, and any kind of cytotoxic systemic anticancer treatment \[hormonal and targeted treatments allowed\])
  * Clinical, biochemical and radiological confirmation of controlled disease (no evidence of residual disease or not-progressive disease)
  * Scheduled for either a therapeutic break (from cytotoxic systemic anticancer treatment), or having completed the planned multimodal treatment
  * Scheduled for active surveillance plan within oncology service or discharged to surgical or GP care following completion of adjuvant treatment
  * Male or female patients aged at least 18 years old
  * WHO Performance Status 0-2

Exclusion Criteria:

* • Not in possession of a SIM card

  * No internet access through Wi-Fi or unwilling to use mobile data allowance on a daily basis
  * Unable to understand and follow the instructions autonomously
  * Uncontrolled severe comorbidities (I.e., cardiovascular, neurological, respiratory)
  * Lack of capacity
  * Unable to understand English
  * Still undergoing systemic anticancer treatment (apart from bone-targeted agents, hormonal treatment against breast or prostate cancers or maintenance monoclonal antibody monotherapy)
  * Poor general condition (PS\>2)

Where this trial is running

Bangor, Gwynedd

• Betsi Cadwaladr University Health board — Bangor, Gwynedd, United Kingdom (Recruiting)

Study contacts

• Study coordinator: Laura Longshaw

Conditions Cancer; Digital Monitoring